Who was studied, and how
Six numbers in the abstract
Where each one falls
Where it lands on the map
2,002people in the Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk trial, from 2018
1,500of them with obesity, in this paper
The trial randomly assignedassigned by chance
tirzepatide 5 mg
insulin glargine
Reported lower long-term blood sugar, no range given−2.30
Reported lower body weight, no range given−7.60
randomisedThe trial randomly assignedassigned by chance
tirzepatide 10 mg
insulin glargine
Reported lower long-term blood sugar, no range given−2.50
Reported lower body weight, no range given−10.0
randomisedthe abstract, start to end
… greater mean reduction in HbA1c (5 mg: -2.3%, 10 mg: -2.5%, 15 mg: -2.6%) compared with the insulin …
… greater reduction in body weight (5 mg: -7.6 kg, 10 mg: -10.0 kg, 15 mg: -11.4 kg) compared with the insulin …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Mean reduction in HbA1ctirzepatide 5 mg vs insulin glargine
−2.3
Mean reduction in HbA1ctirzepatide 10 mg vs insulin glargine
−2.5
Mean reduction in HbA1ctirzepatide 15 mg vs insulin glargine
−2.6
Reduction in body weighttirzepatide 5 mg vs insulin glargine
−7.6
Reduction in body weighttirzepatide 10 mg vs insulin glargine
−10.0
Reduction in body weighttirzepatide 15 mg vs insulin glargine
−11.4
GIP/GLP-1 & amylin agonistsGlycemic controlBody weight & composition
1 / 4